GT Biopharma Inc. (NASDAQ:GTBP) has a beta of -0.12. The stock’s Relative Strength Index (RSI) is 50.38, with weekly volatility at 19.33% and ATR at 1.00. The GTBP stock’s 52-week price range has touched low of $1.53 and a $13.09 high. Its shares traded higher over the last trading session, gaining 28.85% on 03/09/21. The shares fell to a low of $5.16 before closing at $5.85. Intraday shares traded counted 4.47 million, which was -2059.37% lower than its 30-day average trading volume of 207.20K. GTBP’s previous close was $4.54 while the outstanding shares total 4.51M.
Investors have identified the Biotechnology company GT Biopharma Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $134.43 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
GT Biopharma Inc. (GTBP) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For GTBP, the company has in raw cash 0.35 million on their books with 23.0 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 0.83 million total, with 30.69 million as their total liabilities.
Is the stock of GTBP attractive?
In the last 6 months, insiders have changed their ownership in shares of company stock by 0.90%.